STOCK TITAN
  1. Home
  2. News
  3. LEGN

Legend Biotech Corp - LEGN STOCK NEWS

Welcome to our dedicated news page for Legend Biotech (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Legend Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Legend Biotech's position in the market.

News
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) announced that patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study showed clinically meaningful improvement in health-related quality of life following a single CARVYKTI® infusion in adults lenalidomide-refractory multiple myeloma (MM) patients. The as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall response. Longer-term data from CARTITUDE-2 showed deep and durable responses in earlier lines of treatment among patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
News
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial results for the three and nine months ended September 30, 2023. The company entered into an exclusive, global license agreement with Novartis Pharma AG for potential chimeric antigen receptor T-cell (CAR-T) therapies targeting Delta-like ligand 3 (DLL3). Novartis will pay an upfront payment of $100 million and up to $1.01 billion in milestone payments. CARVYKTI® generated approximately $152 million in net trade sales during the quarter, representing a 30% increase over the previous quarter. The company also received milestone payments and appointed a new General Counsel. Legend Biotech has $1.4 billion in cash and cash equivalents, deposits, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
earnings
-
News
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) has entered into an exclusive, global license agreement with Novartis Pharma AG for certain chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102. Legend Biotech will receive a $100M upfront payment and will be eligible to receive potential milestone payments plus tiered royalties on net sales. The deal aims to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting DLL3, using the Novartis next-generation T-Charge™ CAR-T cell therapy platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
News
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will host a conference call on November 20, 2023, to review third-quarter results and provide an overview of its performance for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
News
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
Rhea-AI Summary
Legend Biotech Corporation will present new and updated data from the CARTITUDE clinical development program for ciltacabtagene autoleucel (cilta-cel) at the 65th American Society of Hematology Annual Meeting. The presentations will include patient-reported outcomes from the Phase 3 CARTITUDE-4 study and updated efficacy and safety data from Cohorts A and B of the Phase 2 CARTITUDE-2 study. The company aims to deliver additional treatment options to patients with unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
-
News
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) submitted sBLA and Type II Variation Application for CARVYKTI® to FDA and EMA, seeking approval for earlier treatment of patients with relapsed or refractory multiple myeloma. New data from clinical studies were presented at ASCO and EHA. Financial results for the three and six months ended June 30, 2023, reported $1.5 billion in cash and cash equivalents, time deposits, and short-term investments. Legend Biotech received milestone payments and completed financings in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
earnings
News
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences earnings
-
News
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
News
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
News
Legend Biotech Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will participate in upcoming investor conferences: Jefferies Healthcare Conference on June 7, 2023, and Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock LEGN logo
Legend Biotech Corp

Nasdaq:LEGN

LEGN Rankings

#904 Ranked by Market Cap
#704 Ranked by Stock Gains
N/A Ranked by Dividends

LEGN Stock Data

9.63B
158.77M
1.32%
48.72%
5.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Somerset

About LEGN

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o